{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05096234",
            "orgStudyIdInfo": {
                "id": "IRB-56655"
            },
            "secondaryIdInfos": [
                {
                    "id": "CCT5038",
                    "type": "OTHER",
                    "domain": "OnCore"
                }
            ],
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma",
            "officialTitle": "Pilot Study of [18F]F-AraG PET Imaging to Evaluate Immunological Response to Chimeric Antigen Receptor (CAR) T Cell Therapy in Lymphoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "f-arag-pet-imaging-to-evaluate-immunological-response-to-car-t-cell-therapy-in-lymphoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-09-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-10-14",
            "studyFirstSubmitQcDate": "2021-10-14",
            "studyFirstPostDateStruct": {
                "date": "2021-10-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-05-15",
            "lastUpdatePostDateStruct": {
                "date": "2023-05-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "David Miklos",
                "investigatorTitle": "Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Stanford University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "CellSight Technologies, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.",
            "detailedDescription": "Primary Objectives:\n\n\\* Explore the relationship of change in \\[18F\\]F-AraG PET signal following CAR T cell treatment with changes in T cell infiltration in tumor biopsies.\n\nExploratory Analyses:\n\n* Explore the relationship of change in \\[18F\\]F-AraG PET signal in tumor lesions following CAR T cell treatment with clinical benefit rate (defined as Complete Response (CR) + Partial Response (PR) + stable disease (SD) \u2265 3 months) using RECISTv1.1 criteria\n* Correlate the change in \\[18F\\]F-AraG PET signal in tumor lesions following CAR T cell therapy with maximum grade of Cytokine Release Syndrome (CRS) and neurotoxicity experienced."
        },
        "conditionsModule": {
            "conditions": [
                "Non-Hodgkin's Lymphoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 6,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "[18F]F-AraG PET",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects will undergo PET imaging at the following time points:\n\n* Baseline, prior to lymphodepleting chemotherapy: \\[18F\\]F-AraGPET/CT, followed the next day by FDG-PET/CT\n* At peak CAR expansion: Day 4 (\u00b1 2 days) post-CAR infusion:\n\n  \\[18F\\]F-AraG PET\n* At Day +28 (\u00b1 4 days) post-CAR infusion: FDG-PET/CT Subjects will have a paired biopsy after each imaging time point, if possible. Subjects will be followed for safety of \\[18F\\]F-AraG for 30 days after last dose",
                    "interventionNames": [
                        "Drug: [ 18F]F-AraG PET"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "[ 18F]F-AraG PET",
                    "description": "Dose: 5 mCi (\u00b110%) Mode of Administration: Intravenous (IV)",
                    "armGroupLabels": [
                        "[18F]F-AraG PET"
                    ],
                    "otherNames": [
                        "[ 18F]F-AraG (2'-deoxy-2'-fluoro-9-\u03b2-D- arabinofuranosylguanine; trade name VisAcT)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Primary outcome measure",
                    "description": "Spearman correlation between changes in SUV in \\[18F\\]F-AraG signal on PET imaging to changes in T-cell infiltrates in biopsy samples",
                    "timeFrame": "values obtained on Day 0 and Day 4 (\u00b1 2 days)"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "First exploratory outcome measure",
                    "description": "correlation between changes in SUV \\[18F\\]F-AraG signal on PET imaging to the observed clinical benefit rate using RECISTv1.1 criteria.",
                    "timeFrame": "\u2265 3 months"
                },
                {
                    "measure": "Second exploratory outcome measure",
                    "description": "Correlation between changes in \\[18F\\]F-AraG signal to the frequency and grade of two common CAR T cell toxicities, cytokine release syndrome (CRS) and neurotoxicity, if observed in this study population.",
                    "timeFrame": "\u2265 3 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years old\n* Histologically confirmed aggressive B cell NHL including the following types defined by WHO 2008:\n\n  * DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of the elderly; OR\n  * primary mediastinal (thymic) large B cell lymphoma\n  * transformation of follicular lymphoma, marginal zone lymphoma or chronic lymphocytic leukemia to DLBCL will also be included\n* Measurable disease by PET imaging (as defined by Cheson (2014)), that meets all the following criteria:\n\n  * At least one measureable lesion away from head \\& neck, liver, kidneys, GI tract and bladder\n  * At least one biopsy-accessible lesion or lymph node.\n* Express willingness to undergo low risk FNA or core biopsy of subcutaneous accessible lesion or lymph node.\n* Scheduled to receive commercial or research CAR T cell therapy with axicabtagene ciloleucel (Yescarta \u00ae) as part of anticancer therapy.\n* Adequate renal and hepatic function, defined as:\n\n  1. Creatinine clearance (as estimated by Cockcroft Gault) \u2265 60 mL/min or Cr \\< 1.6 mg/dL\n  2. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \u2264 2.5x upper limit of normal (ULN)\n  3. Total bilirubin \u2264 1.5 mg/dL, except in cases of Gilbert's syndrome\n* Able to give informed consent. Subjects unable to give informed consent will not be eligible for this study\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding.\n* Subjects with significant GI disease involvement by PET imaging\n* In the investigator's judgment, have any medical condition likely to interfere with assessment of safety or efficacy, be unable to tolerate additional radiation, or be unlikely to complete all protocol-required visits and procedures.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Maria Iglesias",
                    "role": "CONTACT",
                    "phone": "650-723-4247",
                    "email": "mariaigl@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "David Miklos, MD, PhD",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University, School of Medicine",
                    "status": "RECRUITING",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Maria Iglesias",
                            "role": "CONTACT",
                            "email": "mariaigl@stanford.edu"
                        },
                        {
                            "name": "David Miklos",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}